First Prescriptions for Innovative Drug Lumeblue® Issued in China
2024-12-06

First Prescriptions for Innovative Drug Lumeblue® Issued in China

Gained Exclusive Commercialization Right of Class 1 Innovative Drug Targeting Gout and Hyperuricemia
2024-12-02

Gained Exclusive Commercialization Right of Class 1 Innovative Drug Targeting Gout and Hyperuricemia

Self-developed Innovative Drug Dual Agonist of Glucagon-like Peptide-1 Receptor/Glucagon Receptor CMS-D005 is Approved for Drug Clinical Trials
2024-11-27

Self-developed Innovative Drug Dual Agonist of Glucagon-like Peptide-1 Receptor/Glucagon Receptor CMS-D005 is Approved for Drug Clinical Trials

New Drug Application of Ruxolitinib Phosphate Cream for Vitiligo Approved in Hong Kong
2024-11-05

New Drug Application of Ruxolitinib Phosphate Cream for Vitiligo Approved in Hong Kong

China Medical System Included in the “Top 20 Chinese Pharmaceutical Listed Companies in ESG Competitiveness” for Three Consecutive Years, with New Honor of the “Top 10 Low-Carbon Pioneers”
2024-10-21

China Medical System Included in the “Top 20 Chinese Pharmaceutical Listed Companies in ESG Competitiveness” for Three Consecutive Years, with New Honor of the “Top 10 Low-Carbon Pioneers”

First Ruxolitinib Cream’s Prescriptions for Vitiligo Issued in the Greater Bay Area
2024-10-18

First Ruxolitinib Cream’s Prescriptions for Vitiligo Issued in the Greater Bay Area

CMS’s Subsidiary Shenzhen Kangzhe Listed in “Shenzhen Top 500 Enterprises” for Four Consecutive Years
2024-09-27

CMS’s Subsidiary Shenzhen Kangzhe Listed in “Shenzhen Top 500 Enterprises” for Four Consecutive Years

New Drug Application for Vitiligo Indication of Ruxolitinib Phosphate Cream Accepted in China
2024-09-24

New Drug Application for Vitiligo Indication of Ruxolitinib Phosphate Cream Accepted in China

NDA for Additional Rheumatoid Arthritis Indication of Methotrexate Injection Approved in China
2024-08-05

NDA for Additional Rheumatoid Arthritis Indication of Methotrexate Injection Approved in China

Receiving “AA” once again in MSCI ESG Rating, being positioned at the industry leading level globally
2024-07-16

Receiving “AA” once again in MSCI ESG Rating, being positioned at the industry leading level globally

Included in S&P Global’s 2024 Sustainability Yearbook (China Edition)

Included in S&P Global’s 2024 Sustainability Yearbook (China Edition)

Innovative Drug Methylthioninium Chloride Enteric-coated Sustained-release Tablets (Lumeblue®) Approved for Marketing in China
2024-06-18

Innovative Drug Methylthioninium Chloride Enteric-coated Sustained-release Tablets (Lumeblue®) Approved for Marketing in China